NVS - Novartis AG
| Previous close | 77.15 |
| Open | 77.38 |
| Bid | 75.80 x 3100 |
| Ask | 78.64 x 1300 |
| Day's range | 76.91 - 77.43 |
| 52-week range | 75.73 - 94.19 |
| Volume | 1,478,946 |
| Avg. volume | 1,706,180 |
| Market cap | 179.633B |
| Beta | 0.89 |
| PE ratio (TTM) | 23.71 |
| EPS (TTM) | 3.25 |
| Earnings date | N/A |
| Forward dividend & yield | 2.98 (3.80%) |
| Ex-dividend date | 2018-03-06 |
| 1y target est | 88.16 |
- Bloomberg Video•5 days ago
Novartis General Counsel Out Over Cohen Contract
May.16 -- Novartis AG’s top lawyer, Felix Ehrat, became the first executive to take the fall for the controversial $1.2 million in payments he helped arrange to President Donald Trump’s attorney Michael Cohen. Bloomberg's Drew Armstrong reports on "Bloomberg Markets: Balance of Power."
CNBC•2 hours agoInvestors have shrugged off Trump drug price plan, but it is still early days
Biotech companies and pharmacy benefit managers defied the overall market trend, despite more noise about President Trump's drug plan.
- CNBC•3 days ago
Cohen lawyers object to Stormy Daniels' attorney Michael Avenatti intervening in New York case
Cohen is under federal criminal investigation for, among other things, a $130,000 payment to the porn star Stormy Daniels in exchange for her silence about an alleged affair with President Trump in 2006.
CNBC•3 days agoMigraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst
Aimovig from Amgen and Novartis could become a $1 billion to $2 billion business in five years, say one Wall Street analyst.
- Zacks•3 days ago
Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.
- The Wall Street Journal•3 days ago
New Migraine Drugs Offer Hope to Sufferers
The FDA has approved a new drug called Aimovig that is touted as the first treatment designed specifically to prevent migraines.
- MarketWatch•3 days ago
‘Holy of holies’ — Inside the financial crime database that sprung a leak
A blockbuster story about the whistleblower who revealed President Donald Trump’s personal lawyer received payments from various companies has placed attention on a fairly obscure unit with the Treasury Department that’s at the heart of regulating the financial system. The New Yorker’s Ronan Farrow interviewed someone he called a “law-enforcement official” who leaked, per the report, after not being able to find two suspicious-activity reports on Michael Cohen, who received big payments from AT&T, Novartis and Korea Aerospace Industries.
- Zacks•3 days ago
Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up
Amgen's (AMGN) preventive treatment for migraine, Aimovig, gets approval in the United States.
- Market Realist•3 days ago
Label Expansion May Boost Cabometyx’s Revenue in 2018
On January 16, Exelixis (EXEL) and Ipsen announced positive results from the CELESTIAL Phase 3 trial highlighting the statistically significant and clinically meaningful improvement in the trial’s primary end point of overall survival due to cabozantinib therapy compared to a placebo in second-line and third-line hepatocellular carcinoma (or HCC) patients.
- Market Realist•3 days ago
Amgen Stock Rises over 2% on Drug Approvals
On May 17, Amgen (AMGN) stock rose ~0.5% to the closing price of $174.65 per share following FDA approval of Aimovig. The company’s stock price has risen ~2.3% in the last week following recent drug approvals. Amgen’s stock price has risen ~11.2% over the last 12 months.
Market Realist•3 days agoCabometyx Is Expected to Witness a Robust Revenue Rise in 2018
In the first quarter, Exelixis’s (EXEL) Cabometyx witnessed more than a 20% sequential rise in prescription volume driven by both new patient starts and a robust rise in the total number of patients on the therapy. According to a report, ~295,000 people across the world are diagnosed with kidney cancer every year, while 134,000 kidney cancer patients die every year. According to the American Cancer Society’s Cancer Facts & Figures 2018, the annual incidence of kidney cancer in the United States is ~65,000, while the annual death toll of the disease is 15,000. Another report estimates that almost 70%–75% of renal cell cancer (or RCC) patients suffer from clear cell RCC.
- MarketWatch•3 days ago
FDA approves anti-migraine drug from Novartis, Amgen
Shares of drugmakers Amgen Inc. and Novartis AG rose in after-hours trading Thursday after jointly announcing FDA approval of Aimovig, a first-of-its-kind treatment for migraines. In a statement, Novartis said the Federal Drug Administration approved Aimovig's use for the preventive treatment of migraines in adults. "Aimovig is the first therapy of its kind targeting the CGRP receptor, and has demonstrated robust efficacy across the spectrum of migraine," Novartis Chief Executive Paul Hudson said in the statement.
Associated Press•4 days agoUS approves 1st drug developed to prevent chronic migraines
TRENTON, N.J. (AP) — U.S. regulators Thursday approved the first drug designed to prevent chronic migraines.
Associated Press•4 days agoFDA names drugmakers accused of blocking cheaper generics
TRENTON, N.J. (AP) — U.S. drug regulators are publicizing information on brand-name drugmakers that use what government officials call "gaming tactics" to block cheaper copycat versions.
- Market Realist•4 days ago
Exelixis Focused on Positioning Cabometyx in Kidney Cancer Space
Exelixis (EXEL) aims to position Cabometyx as the preferred tyrosine-kinase inhibitor (or TKI) in the renal cell carcinoma (or RCC) segment. At the end of 2017, Cabometyx had managed to acquire a 42% share of the second-line and new patient advanced RCC market, higher than its 39% market share at the end of the third quarter of 2017. Cabometyx demonstrated superiority over Pfizer’s (PFE) Sutent as a first-line RCC therapy in its Phase 2 CABOSUN trial in terms of progression-free survival, which has helped boost physicians’ confidence in Cabometyx.
- The Wall Street Journal•4 days ago
[$$] Novartis Top Lawyer Departs Over Cohen Payments
ZURICH——A top executive at Swiss drugmaker Novartis AG is stepping down amid the controversy over payments that corporations made to a company owned by U.S. President Donald Trump’s longtime personal lawyer . Novartis said Wednesday that general counsel Felix Ehrat, 61 years old, is retiring from the company in connection with $1.2 million in payments it made over the course of a year to Michael Cohen’s shell company, Essential Consultants LLC. It was the second high-profile departure in less than a week in relation to payments to the company.
- Market Realist•4 days ago
Novartis Gains Ground, Completes the AveXis Acquisition
Novartis (NVS) is one of the leading pharmaceutical companies worldwide. AveXis (AVXS) is a US-based clinical-stage gene therapy company. On May 15, Novartis announced that it completed the acquisition of AveXis.
CNBC•4 days agoMissing documents prompted leak of Trump lawyer Michael Cohen's bank records: Report
A law enforcement official leaked a suspicious activity report about Trump lawyer Michael Cohen and payments by Novartis and AT&T to his Essential Consultants company, The New Yorker reports.
- The Wall Street Journal•4 days ago
[$$] The Novartis-Cohen Connection Explained
Although other companies, including AT&T, also paid Mr. Cohen for his services, Novartis is distinguished for likely having paid more than any of the others, and it has drawn the attention of prosecutors at home. Novartis is a Basel-based multinational pharmaceutical company that makes a number of drugs, including treatments for cancer, heart conditions, and autoimmune diseases.
- Bloomberg•5 days ago
Novartis General Counsel Out Over Cohen Contract
Novartis AG’s top lawyer, Felix Ehrat, became the first executive to take the fall for the controversial $1.2 million in payments he helped arrange to President Donald Trump’s attorney Michael Cohen. Bloomberg's ...
- MarketWatch•5 days ago
Here’s how Novartis’s former CEO explained hiring Michael Cohen
Joseph Jimenez, the former chief executive of Novartis, has an explanation for why the Swiss pharmaceutical lavished President Donald Trump’s personal lawyer Michael Cohen with a $1.2 million consulting contract. The hiring of Cohen by Novartis (NVS) , AT&T Inc. (XNYS:T) and Korea Aerospace Industries — revealed by the lawyer of the adult-film star who has alleged having an affair with Trump — has set off a firestorm in Washington and opened up the companies to potential legal liability.
- Bloomberg•5 days ago
How Trump's Fix-It Man Became a $1.2 Million Headache for Novartis
When Michael Cohen showed up at Novartis AG last year proposing to help the drugmaker navigate the Donald Trump administration, it sounded like a promising opportunity. Cohen had, after all, served as an attorney for Trump and had close ties to the new president. It didn’t take long for Novartis to conclude Cohen was full of hot air.
Reuters•5 days agoNovartis top lawyer exits over Trump attorney deal 'mistake'
Novartis's top lawyer quit on Wednesday over a $1.2 million contract he co-signed with U.S. President Donald Trump's personal attorney, a deal the Swiss drugmaker's ex-CEO also said was a mistake. The contract with Michael Cohen's Essential Consultants, the same firm used to pay porn star Stormy Daniels, has distracted Novartis's efforts to improve its image after a series of missteps. Current CEO Vas Narasimhan also said the contract was a major mistake at a meeting with investors in Basel on Wednesday and said Novartis was developing a principles-, not rules-based system to help avert corruption and guide employees' behaviour.
Reuters•5 days agoNovartis top lawyer exits over Trump attorney deal 'mistake'
Novartis's (NOVN.S) top lawyer quit on Wednesday over a $1.2 million contract he co-signed with U.S. President Donald Trump's personal attorney, a deal the Swiss drugmaker's ex-CEO also said was a mistake. The contract with Michael Cohen's Essential Consultants, the same firm used to pay porn star Stormy Daniels, has distracted Novartis's efforts to improve its image after a series of missteps. Current CEO Vas Narasimhan also said the contract was a major mistake at a meeting with investors in Basel on Wednesday and said Novartis was developing a principles-, not rules-based system to help avert corruption and guide employees' behavior.
Yahoo Finance•5 days agoDow seesaws, hedge funds make surprising tech giant trades
Yahoo Finance's LIVE market coverage and analysis of stocks and bonds begins each day at 11:45 a.m. ET.
